-
EP2099753
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2099753
| EP2099753 - HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS [Right-click to bookmark this link] | Status | The application has been withdrawn Status updated on 17.07.2015 Database last updated on 15.06.2024 | Most recent event Tooltip | 17.07.2015 | Withdrawal of application | published on 19.08.2015 [2015/34] | Applicant(s) | For all designated states SANOFI 54, rue La Boétie 75008 Paris / FR | [N/P] |
| Former [2012/18] | For all designated states SANOFI 54 rue La Boétie 75008 Paris / FR | ||
| Former [2012/17] | For all designated states SANOFI 54, rue de la Boétie 75008 Paris / FR | ||
| Former [2011/30] | For all designated states SANOFI 174, Avenue de France 75013 Paris / FR | ||
| Former [2009/38] | For all designated states Sanofi-Aventis 174 Avenue de France 75013 Paris / FR | Inventor(s) | 01 /
STROBEL, Hartmut Sanofi-Aventis Deutschland GmbH 65926 Frankfurt am Main / DE | 02 /
WOHLFART, Paulus Sanofi-Aventis Deutschland GmbH 65926 Frankfurt am Main / DE | 03 /
KLEEMANN, Heinz-Werner Sanofi-Aventis Deutschland GmbH 65926 Frankfurt am Main / DE | 04 /
ZOLLER, Gerhard Sanofi-Aventis Deutschland GmbH 65926 Frankfurt am Main / DE | 05 /
WILL, David William Sanofi-Aventis Deutschland GmbH 65926 Frankfurt am Main / DE | [2009/38] | Representative(s) | Kujath, Eckard, et al Sanofi-Aventis Deutschland GmbH Global Intellectual Property Department Industriepark Höchst Gebäude K 703 65926 Frankfurt am Main / DE | [N/P] |
| Former [2009/38] | Kujath, Eckard, et al Sanofi-Aventis Deutschland GmbH Patent- und Lizenzabteilung Industriepark Höchst Gebäude K 801 65926 Frankfurt am Main / DE | Application number, filing date | 07856485.3 | 08.12.2007 | [2009/38] | WO2007EP10709 | Priority number, date | EP20060026397 | 20.12.2006 Original published format: EP 06026397 | [2009/38] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2008074413 | Date: | 26.06.2008 | Language: | EN | [2008/26] | Type: | A2 Application without search report | No.: | EP2099753 | Date: | 16.09.2009 | Language: | EN | The application published by WIPO in one of the EPO official languages on 26.06.2008 takes the place of the publication of the European patent application. | [2009/38] | Search report(s) | International search report - published on: | EP | 07.08.2008 | Classification | IPC: | C07D213/50, C07D401/06, C07D407/06, C07D409/06, C07D409/14, C07D413/06, C07D417/06, A61P9/00, A61K31/4523 | [2009/38] | CPC: |
C07D213/56 (EP,US);
A61P1/16 (EP);
A61P11/08 (EP);
A61P13/10 (EP);
A61P15/10 (EP);
A61P15/12 (EP);
A61P19/10 (EP);
A61P25/00 (EP);
A61P25/28 (EP);
A61P27/02 (EP);
A61P3/00 (EP);
A61P3/10 (EP);
A61P43/00 (EP);
A61P7/02 (EP);
A61P9/00 (EP);
A61P9/02 (EP);
A61P9/04 (EP);
A61P9/06 (EP);
A61P9/10 (EP);
A61P9/12 (EP);
C07D213/64 (EP,US);
C07D213/73 (EP,US);
C07D213/75 (EP,US);
C07D215/12 (EP,US);
C07D233/64 (EP,US);
C07D233/68 (EP,US);
C07D239/26 (EP,US);
C07D277/30 (EP,US);
C07D277/46 (EP,US);
C07D333/24 (EP,US);
C07D333/60 (EP,US);
C07D401/06 (EP,US);
C07D401/12 (EP,US);
C07D405/12 (EP,US);
C07D409/04 (EP,US);
C07D409/06 (EP,US);
C07D409/12 (EP,US);
C07D413/06 (EP,US);
C07D417/06 (EP,US);
C07D417/12 (EP,US)
(-)
| Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR [2009/38] | Title | German: | HETEROARYLACRYLAMIDE UND IHRE VERWENDUNG ALS PHARMAZEUTIKA | [2009/38] | English: | HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | [2009/38] | French: | HÉTÉROARYLACRYLAMIDES ET LEUR UTILISATION EN TANT QUE PRODUITS PHARMACEUTIQUES | [2009/38] | Entry into regional phase | 20.07.2009 | National basic fee paid | 20.07.2009 | Designation fee(s) paid | 20.07.2009 | Examination fee paid | Examination procedure | 04.10.2008 | Request for preliminary examination filed International Preliminary Examining Authority: EP | 20.07.2009 | Examination requested [2009/38] | 22.07.2010 | Despatch of a communication from the examining division (Time limit: M06) | 10.03.2011 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | 16.05.2011 | Reply to a communication from the examining division | 25.06.2014 | Despatch of a communication from the examining division (Time limit: M06) | 18.12.2014 | Reply to a communication from the examining division | 14.07.2015 | Application withdrawn by applicant [2015/34] | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 22.07.2010 | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the examination report | 16.05.2011 | Request for further processing filed | 16.05.2011 | Full payment received (date of receipt of payment) Request granted | 25.05.2011 | Decision despatched | Fees paid | Renewal fee | 04.01.2010 | Renewal fee patent year 03 | 15.12.2010 | Renewal fee patent year 04 | 12.12.2011 | Renewal fee patent year 05 | 11.12.2012 | Renewal fee patent year 06 | 12.12.2013 | Renewal fee patent year 07 | 11.12.2014 | Renewal fee patent year 08 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X]US6369002 (KUNZ WALTER [CH], et al) [X] 1-9 * e.g some compounds of table 56, 57 or 216 having Cl as R1 and CH=CHCONH2 as R3. *; | [X]WO2004039365 (TAKEDA CHEMICAL INDUSTRIES LTD [JP], et al) [X] 1-14 * examples 168,180,182,183,204,209 *; | [X]US2004121994 (ANDERSON STEVEN N [US], et al) [X] 1-14 * claim 1 *; | [A]WO2004014842 (AVENTIS PHARMA GMBH [DE]) [A] 1-14 * the whole document * | Examination | EP0630894 | US4994453 | EP0344979 | - HARADA HITOSHI ET AL, "2-alkynyl-8-aryl-9-methyladenines as novel adenosine receptor antagonists:their synthesis and structure-activity relationships toward hepatic glucose production induced vai agonism of the A2B receptor", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, (20010101), vol. 44, no. 2, doi:10.1021/JM990499B, ISSN 0022-2623, pages 170 - 179, XP002904618 DOI: http://dx.doi.org/10.1021/jm990499b |